3D Cell Culture Market Analysis

3D Cell Culture Market Overview

The 3D cell culture market size was valued at USD 1.61 billion in 2021 and is projected to grow from USD 1.81 billion in 2022 to USD 4.98 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.47% during the forecast period (2023 - 2032). Increasing adoption of 3D cell culture and rising strategic initiatives for 3D cell culture are fueling the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

3D BioFibR, based in Canada, got an investment amounting to nearly $3.52 million from another party to expand its facility and create collagen fiber products employed for the purpose of 3D bioprinting.

Corning Life Sciences revealed plans in February 2023 about their forthcoming cutting-edge tools for use in advanced three-dimensional culture techniques and a new Elplasia plate integrated with an open-well format enabling easy manipulation of spheroids and organoids.

The PhysioMimix by CN Bio was released as a commercial product line in February 2023, and it is designed as a single-organ high-throughput system. The introduction of such devices early on within the drug discovery workflow could permit more rapid adoption of predictive models such as human liver Organ-on-a-Chip. With the deployment of 3D cell culture systems, including PhysioMimix, researchers can simulate organ and tissue behavior more effectively for more meaningful and reliable preclinical research outcomes.

3D Cell Culture Market Trends

• 
  

  Increasing adoption of 3D cell culture boosts market growth.

  
  

There are several factors that are increasing the adoption of 3D cell culture. Some of the most predominant ones include the rising incidences of chronic diseases and the increasing preference for precision medicine, owing to the emerging approach to the prevention and treatment of diseases. As well, 3D cell culture provides tremendous advantages, such as tissue engineering, which specializes in repairing damaged tissues and reduces the gap between in vitro and in vivo drug testing models for pharmaceutical and biotechnological companies. Hence, it is speeding up the development of the drug for chronic diseases such as cancer and diabetes, which is propelling the growth of the market.

Additionally, the rise in the number of various strategic initiatives by various public and private organizations, including product launches, mergers, acquisitions, regulatory approvals, and collaborations for numerous diseases, is positively contributing to market growth. For instance, in February 2019, Thermo Fisher Scientific, Inc. (US) launched the CytoVista tissue clearing reagents, which are designed for use in 3D cell culture.

3D Cell Culture Market Segment Insights

3D Cell Culture Technique Insights

The 3D cell culture market segmentation, based on technique, scaffolds based 3D cell culture and scaffold-free 3D cell culture. The scaffolds based 3D cell culture further segmented into hydrogel-based support and scaffold-free 3D cell culture segmented into hanging drop microplates, spheroid microplates containing ultra-low attachment (ULA) coating, and microfluidic 3D cell culture. The scaffolds based 3D cell culture segment is expected to register the highest CAGR from 2022 to 2030. This is due to an increase in awareness about the benefits of scaffold cell culture, such as the facilitation of oxygen, waste transport, and nutriment, can contribute to the market's upsurge in the analysis period.

3D Cell Culture Product Insights

Based on product, the global market segmentation for 3D cell culture includes consumables and instruments. The consumables have been segmented into culture media, reagents, 3D multiwell plates, and glassware, moreover the instruments further have been segmented into bioreactor, flow cytometer, and cell culture chips. The consumables segment is expected to show the largest market share in 2021, owing to the easy accessibility of raw materials such as hydrogel and others. Furthermore, increasing demand for precision medicine and rising incidences of severely rare diseases are helping to generate large revenues from the consumable segments.

3D Cell Culture Application Insights

The market of 3D cell culture has been segmented by application into drug discovery, cancer research, stem cell research, tissue screening & engineering, regenerative medicine, toxicity testing, and others. The drug discovery segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This is due to advantages 3D cell offering in discovering the drug molecule and speeds up the drug discovery process. The advantages of deploying the same has been immense such as 3D cell culture can easily avoid human errors, improve decision-making, process data faster, and avoid repetitive tasks.

Figure 2: 3D cell culture market, by Application, 2021 & 2030 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

3D Cell Culture End User Insights

Based on end user, the global 3D cell culture industry has been segmented into pharmaceutical & biotechnology companies, contract research organizations, and research & academic laboratories. The pharmaceutical & biotechnology companies segment dominated the market in 2021 and is projected to be the fastest-growing segment during the forecast period. The pharmaceutical & biotechnology companies segment is the major end-user owing to the rising prevalence of chronic diseases as well as offer tremendous advantages such as speeding the development of drugs with safety and efficacy and eliminating human errors which reduce the burden on the workforce.

3D Cell Culture Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America 3D cell culture market accounted for the largest market share because 3D culture in drug discovery is heavily adopted by North America pharmaceutical and biotechnology companies. According to the study, the North American region has seen the most widespread adoption of 3D culture across all industries. However, due to the increasing prevalence of diseases, the pharma and biotech industries are heavily utilizing 3D culture in drug discovery.

Further, the major countries studied are: The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: 3D CELL CULTURE MARKET SHARE BY REGION 2021 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe market for 3D Cell Culture accounts for the second-largest market share due to the high adoption of technological advancements and increasing prevalence of rare diseases. For instance, In December 2022, EURORDIS—the European Organization for Rare Diseases—announced that 30 million people were suffering from rare diseases. Furthermore, the Germany 3D cell culture market held the largest market share, and the UK market was the fastest growing in the Europe region.

The Asia-Pacific market of 3D Cell Culture is expected to grow at a significant share from 2022 to 2030, owing to rising burden of disease and the huge number of biopharmaceutical industries that are adoption 3D culture for drug discovery to reduce the drug development time. Furthermore, increasing incidences of diseases such as diabetes and obesity further pressurize to speed up the development of innovative and effective drug and due to this companies are adopting 3D cell culture. Moreover, China market of 3D cell culture held the largest share, and the India market of 3D cell culture was the fastest growing market in the Asia-Pacific region.

3D Cell Culture Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the 3D cell culture market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the 3D cell culture industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Corning Incorporated (US) is a leading producer manufacturer of glass and ceramic materials for use in a wide range of industries, including semiconductors, LCDs, optical fibre, solar energy, and packaging. In addition, the company manufactures a variety of other products for industrial and scientific applications. In January 2020, the company's product portfolio has expanded to include Corning Elplasia plates with microcavity technology for spheroid production and Matrigel matrix for organoid culture. These new solutions support cell therapy research.

Additionally, Lonza Group AG, headquartered in Basel, Switzerland, is a multinational chemical and biological manufacturing company. It is a leader in the creation of innovative 3D cell culture solutions. Its primary focus is the development and manufacturing of products and services that assist in the advancement of cell-based therapies. In June 2020, Lonza Group AG and CELLINK (Sweden) collaborated to provide a comprehensive three-dimensional (3D) bioprinting solution designed to advance full three-dimensional (3D) cell culture workflows

Key Companies in the 3D cell culture market includes.

• Corning Incorporated (US)


• Lonza Group AG (Switzerland)


• Thermo Fisher Scientific, Inc. (US)


• Merck KGaA (Germany)


• Avantor, Inc. (US)


• Tecan Trading AG (Switzerland)


• 3D Biotek LLC (US)


• REPROCELL, Inc. (Japan)


• Kirkstall Ltd. (UK)


• MIMETAS BV (Netherlands), among others.

3D Cell Culture Industry Developments

Basel, Switzerland, July 2024 Lonza reported CHF 3.1 billion in sales, increasing 1.8%1 CER (-0.7% AER)2. A strong margin of 29.2% was achieved by CHF 893 million in CORE EBITDA, thanks to a favorable product mix and ongoing demand for commercial CDMO services Growth in H1 was driven by good momentum in Biologics, supported by a strong performance in Bioconjugates. The growth in Biologics was partly offset by lower demand in the capsules business within the CHI division.

The signing of an agreement to purchase Genentech's large-scale mammalian facility in Vacaville, US, from Roche was one of the company's highlights in H1. As planned, the transaction will close in the fourth quarter of 2024. In addition, Lonza announced the appointment of Wolfgang Wienand as its new CEO, who began working for the company on July 1st, and welcomed Jean-Marc Huët as the new Chairman of the Board of Directors.

July 2023

REPROCELL Inc. has formed a partnership with Vernal Biosciences to provide mRNA services at scale for clinical and research purposes in Japan. This strategy is consistent with REPROCELL's mission to bring cutting-edge preclinical and clinical research solutions to market.

In January 2023, CD BioSciences launched scaffold-based technology to help scientists achieve organotypic co-culture and simulate layered tissue structures.

3D Cell Culture Market Segmentation

3D Cell Culture Technique Outlook

• 
  
  Hanging Drop Microplates
  
  


• 
  
  Spheroid Microplates Containing Ultra-Low Attachment (ULA) Coating
  
  


• 
  
  Microfluidic 3D Cell Culture
  
  

3D Cell Culture Product Outlook

• 
  
  Bioreactor
  
  


• 
  
  Flow Cytometer
  
  


• 
  
  Cell Culture Chips
  
  

3D Cell Culture Application Outlook

• Drug Discovery


• Cancer Research


• Stem Cell Research


• Tissue Screening & Engineering


• Regenerative Medicine


• Toxicity Testing


• Others

3D Cell Culture End User Outlook

• Pharmaceutical & Biotechnology Companies


• Contract Research Organizations


• Research & Academic Laboratories

3D Cell Culture Regional Outlook

• 
  
  Middle East
  
  


• 
  
  Africa
  
  


• 
  
  Latin America